Pancreatic Cancer Research

ResearcherUniversità Cattolica del Sacro CuoreActive in the last 2 years

Stefano Partelli

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8938-6170; OpenAlex author ID A5037000005, A5063976959, A5159676687. Sources: ClinicalTrials.gov.

Their work

Papers
46 (first author 4, last author 1)
Trials
2 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
125
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 3 papers · 2017: 2 papers · 2018: 3 papers, 1 trial · 2019: 4 papers · 2020: 5 papers · 2021: 5 papers · 2022: none · 2023: 5 papers · 2024: 3 papers · 2025: 2 papers · 2026: 7 papers, 1 trial

Papers 46

  1. Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2026.3716↗
  2. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  3. Multicenter IGoMIPS Registry-based analysis of robotic versus laparoscopic approach to left pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s13304-026-02831-3↗
  4. Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results f… Co-author DOI 10.1016/j.eclinm.2026.104190↗
  5. Actual Five-year Survival After Neoadjuvant Therapy and Resection for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000007214↗
  6. Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19218-8↗
  7. ASO Visual Abstract: Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19370-1↗
  8. Anatomically resectable versus biologically borderline resectable pancreatic cancer definition: refining the border beyond anatomical criteria and biological a… Co-author DOI 10.1093/bjsopen/zraf033↗
  9. Prognostic Validation of Perineural Invasion Severity Score in Pancreatic Cancer: A Prospective Study. Co-author DOI 10.1097/sla.0000000000006920↗
  10. Exploring the optimal therapeutic management of stage ypIA pancreatic ductal adenocarcinoma patients in the era of primary chemotherapy. Co-author DOI 10.1016/j.dld.2023.07.006↗
  11. Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrence. Co-author DOI 10.1016/j.surg.2024.07.026↗
  12. Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: Proof of Concept for a "Biological R2 Definition". Co-author DOI 10.1245/s10434-024-15105-2↗
  13. Surgical Planning for "Borderline Resectable" and "Locally Advanced" Pancreatic Cancer During Open Pancreatic Resection. Co-author DOI 10.1007/s11605-023-05848-w↗
  14. The role of biliary events in treatment and survival of patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.dld.2023.04.015↗
  15. Pancreatectomy with venous vascular resection for pancreatic cancer: Impact of types of vein resection on timing and pattern of recurrence. Co-author DOI 10.1016/j.ejso.2023.03.229↗
  16. Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.01.016↗
  17. Consensus Statement on the Use of Near-Infrared Fluorescence Imaging during Pancreatic Cancer Surgery Based on a Delphi Study: Surgeons' Perspectives on Curren… Co-author DOI 10.3390/cancers15030652↗
  18. European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer. Co-author DOI 10.1016/j.ctrv.2021.102208↗
  19. Does chronic consumption of angiotensin-converting enzyme inhibitors affect survival after surgical resection of pancreatic ductal adenocarcinoma? Co-author DOI 10.1016/j.dld.2021.04.027↗
  20. Improved survival after pancreatic re-resection of positive neck margin in pancreatic cancer patients. A systematic review and network meta-analysis. Co-author DOI 10.1016/j.ejso.2021.01.001↗
  21. Recurrence after surgical resection of pancreatic cancer: the importance of postoperative complications beyond tumor biology. Co-author DOI 10.1016/j.hpb.2021.04.004↗
  22. Long-Term Survivors after Upfront Resection for Pancreatic Ductal Adenocarcinoma: An Actual 5-Year Analysis of Disease-Specific and Post-Recurrence Survival. Co-author DOI 10.1245/s10434-021-10401-7↗
  23. A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. Co-author DOI 10.1007/s13304-020-00710-z↗
  24. Statin use improves survival in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Co-author DOI 10.1016/j.dld.2020.01.008↗
  25. Positive neck margin at frozen section analysis is a significant predictor of tumour recurrence and poor survival after pancreatodudenectomy for pancreatic can… Co-author DOI 10.1016/j.ejso.2020.02.013↗
  26. Bratislava Statement: consensus recommendations for improving pancreatic cancer care. Co-author DOI 10.1136/esmoopen-2020-001051↗
  27. The Role of Hyponatraemia Before Surgery in Patients With Radical Resected Pancreatic Cancer. Co-author DOI 10.1177/1179554920936605↗
  28. Prognostic impact of Ki-67 proliferative index in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/bjs5.50175↗
  29. Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis. Co-author DOI 10.1016/j.tranon.2018.08.017↗
  30. Risk and Predictors of Postoperative Morbidity and Mortality After Pancreaticoduodenectomy for Pancreatic Neuroendocrine Neoplasms: A Comparative Study With Pa… Co-author DOI 10.1097/mpa.0000000000001273↗
  31. Postoperative Outcomes and Functional Recovery After Preoperative Combination Chemotherapy for Pancreatic Cancer: A Propensity Score-Matched Study. Co-author DOI 10.3389/fonc.2019.01299↗
  32. SUVmax after (18)fluoro-deoxyglucose positron emission tomography/computed tomography: A tool to define treatment strategies in pancreatic cancer. Co-author DOI 10.1016/j.dld.2017.09.122↗
  33. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreati… Co-author DOI 10.1016/j.ejca.2018.07.007↗
  34. Systematic review and meta-analysis of prognostic role of splenic vessels infiltration in resectable pancreatic cancer. Co-author DOI 10.1016/j.ejso.2017.10.217↗
  35. Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.critrevonc.2017.01.015↗
  36. Pancreatic Ductal Adenocarcinoma: A New TNM Staging System is Needed! First author DOI 10.1097/sla.0000000000001921↗
  37. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.critrevonc.2015.11.016↗
  38. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Co-author DOI 10.1016/j.ejso.2016.06.398↗
  39. [Pancreatic cancer]. Last author DOI 10.1701/2296.24698↗
  40. Adjuvant Chemoradiation in Pancreatic Cancer: A Pooled Analysis in Elderly (≥75 years) Patients. Co-author PMID 26026108↗
  41. The role of (18)fluoro-deoxyglucose positron emission tomography/computed tomography in resectable pancreatic cancer. Co-author DOI 10.1016/j.dld.2014.03.011↗
  42. Time trends in the treatment and prognosis of resectable pancreatic cancer in a large tertiary referral centre. First author DOI 10.1111/hpb.12073↗
  43. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. First author DOI 10.1016/j.amjsurg.2011.03.008↗
  44. Faecal elastase-1 is an independent predictor of survival in advanced pancreatic cancer. Co-author DOI 10.1016/j.dld.2012.05.017↗
  45. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile? First author DOI 10.1016/j.surg.2012.05.017↗
  46. Splenic artery invasion in pancreatic adenocarcinoma of the body and tail: a novel prognostic parameter for patient selection. Co-author DOI 10.1245/s10434-011-1769-1↗

Trials 2

  1. Optimizing Risk Assessment Through cfDNA in Pancreatic Neuroendocrine Tumors for Clinical Evaluation Principal investigator NCT07817225↗
  2. Diagnostic Accuracy of Preoperative Diagnostic Procedure in the Assessment of Lymph Node Metastases by NF-PanNENs Study director NCT03918759↗

Closest collaborators

The 25 strongest of 125 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Massimo Falconi · 41 shared papers, 2011–2026 · strength 4.98
  2. Stefano Crippa · 33 shared papers, 2011–2026 · strength 4.38
  3. Domenico Tamburrino · 22 shared papers, 2011–2026 · strength 3.37
  4. Giulio Belfiori · 19 shared papers, 2018–2026 · strength 3.16
  5. Michele Reni · 19 shared papers, 2015–2026 · strength 2.68
  6. Giulia Gasparini · 13 shared papers, 2020–2026 · strength 2.28
  7. Marco Schiavo Lena · 10 shared papers, 2020–2026 · strength 1.98
  8. Federico De Stefano · 9 shared papers, 2023–2026 · strength 1.85
  9. Nicolò Pecorelli · 9 shared papers, 2019–2026 · strength 1.74
  10. Diego Palumbo · 7 shared papers, 2024–2026 · strength 1.47
  11. Francesco DE COBELLI · 5 shared papers, 2024–2026 · strength 1.06
  12. Daniela Cesana · 1 shared trial, 2026 · strength 0.95
  13. Paolo Riccardo Camisa · 4 shared papers, 2024–2026 · strength 0.85
  14. Marina Macchini · 5 shared papers, 2018–2026 · strength 0.84
  15. Giulia Orsi · 4 shared papers, 2023–2026 · strength 0.77
  16. Giuseppe Malleo · 3 shared papers, 2026 · strength 0.68
  17. Gabriele Capurso · 4 shared papers, 2020–2026 · strength 0.66
  18. Claudio Doglioni · 4 shared papers, 2018–2025 · strength 0.57
  19. Paolo Giorgio Arcidiacono · 4 shared papers, 2018–2026 · strength 0.57
  20. Gianpaolo Balzano · 5 shared papers, 2016–2026 · strength 0.51
  21. Roberto Salvia · 3 shared papers, 2013–2026 · strength 0.49
  22. Fabio Casciani · 2 shared papers, 2026 · strength 0.46
  23. Gabriella Lionetto Lionetto · 2 shared papers, 2026 · strength 0.46
  24. Claudio Luchini · 2 shared papers, 2026 · strength 0.46
  25. Theodore Sunki Hong · 2 shared papers, 2026 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.